Category: AMyC

This is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.

Continue reading

The Academic Myeloma Consortium (AMyC) was present at the December 2011 ASH meeting. The Consortium is part of the CORE Science Solutions (CSS) group of Consortia focused on collaborating with pharmaceutical and biotech companies on the development of drugs to treat myeloma. CSS is part of the Criterium Inc. group of companies.

Continue reading

Aptium Oncology, a consulting and management company for cancer centers, is putting together a network of investigators specifically focused on myeloma and related cancers. The Aptium Oncology Myeloma Consortium (AMyC) is modeled after Aptium’s GI Cancer Consortium, a group launched in 2008 to focus on gastrointestinal cancers.

Continue reading

Aptium Oncology, Inc. announced the launch of Aptium Oncology Myeloma Consortium (AMyC), a broad-based collaboration that brings together renowned investigators to work with pharmaceutical sponsors to advance clinical and translational research in myeloma and related cancers.

Continue reading